There is currently a tremendous opportunity to strengthen commercial and reimbursement strategies by improving scientific communication on how real world data and evidence support product effectiveness for patients, providers and payers. FDA published the guidance document on, “Real World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision Making for Drug and Biological Products”, in September 2021. This shines the light even brighter on the importance of understanding how to leverage secondary data to complement and innovate clinical trials.

DGE invites you to join your colleagues at the 2nd Real World Evidence and Market Access Symposium to hear about the latest advances and best practices for harnessing the data insights that have the greatest impact on patient care. From identifying and accessing the right data to creating valuable insights that help pave the road to patient access, you will gain the critical approaches needed to focus your message on the patients who will benefit most from your therapy and work to further identify unmet patient needs.